Predictors of residual mass histologyafter chemotherapy for advanced testis cancer

Arthur I Sagalowsky, D. H. Ewalt, Kyle H Molberg, R. C. Peters

Research output: Contribution to journalArticlepeer-review

13 Scopus citations


The records of 15 patients with Stage B3 or B2/C germ cell testis tumors who underwentfull surgical debulking of a residual mass after completion of chemotherapy were reviewed retrospectively to look for predictors of residual mass histology. The density, character, and change in volume of the retroperitoneal mass on computerized tomography before and after chemotherapy were compared with the histology in the primary tumor and in the residual mass. One of 6 patients without teratoma in the primary tumor had a 97 percent reduction in the mass which contained residual teratoma. Two patients with residual seminoma had a 50 percent decrease in tumor volume, and both patients died of tumor progression despite salvage chemotherapy. Two patients with pure serninomas had only residual fibrosis in masses that decreased in volume by 77 and 75 percent, respectively. One of these masses was discrete and the other was diffuse. Seven of 9 patients (78 %) with teratoma in the primary tumor had either teratoma (4 of 9, 44 %) or carcinoma (3 of 9, 33 %) in the residual mass, and the change in mass volume ranged from a 93 percent decrease to a 540 percent increase in size. All 7 patients with residual teratoma and/or carcinoma remain free of disease after observation or further chemotherapy. For the entire series, the mass density and character did not correlate consistently with the primary tumor or residual mass histology. Residual fibrosis alone or teratoma and/or carcinoma were seen with least (0 to 50 %) and greatest (more than 90 %) decreases in mass volume.

Original languageEnglish (US)
Pages (from-to)537-542
Number of pages6
Issue number6
StatePublished - Jun 1990

ASJC Scopus subject areas

  • Urology


Dive into the research topics of 'Predictors of residual mass histologyafter chemotherapy for advanced testis cancer'. Together they form a unique fingerprint.

Cite this